(secondQuint)Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors.

 This is a 2-part dose escalation and dose expansion study.

 Dose escalation uses a modified "3+3" design and continues until a maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified.

 In part 2, subjects with selected tumor types will be enrolled at the MTD or RP2D.

.

 Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors@highlight

HTI-1066 is a novel ADC being developed for the treatment of cancers in patients with overexpression of c-Met.

 This 2-part, Phase 1 study evaluates the safety the tolerability of HTI-1066 in subjects with advanced solid tumors.

